Maryland Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Maryland Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.5K	Buy	+65	New	+$44.2K	0.01%	154
2025 Q4	$50.2K	Hold	65	–	–	0.02%	143
2025 Q3	$36.5K	Hold	65	–	–	0.01%	156
2025 Q2	$34.1K	Hold	65	–	–	0.01%	154
2025 Q1	$41.2K	Hold	65	–	–	0.02%	132
2024 Q4	$46.3K	Sell	65 -65	-50%	-$54.5K	0.02%	133
2024 Q3	$137K	Hold	130	–	–	0.07%	82
2024 Q2	$137K	Hold	130	–	–	0.07%	82
2024 Q1	$125K	Hold	130	–	–	0.08%	83
2023 Q4	$114K	Hold	130	–	–	0.08%	82
2023 Q3	$107K	Hold	130	–	–	0.08%	78
2023 Q2	$93.4K	Hold	130	–	–	0.08%	88
2023 Q1	$107K	Hold	130	–	–	0.09%	83
2022 Q4	$93.8K	Hold	130	–	–	0.09%	86
2022 Q3	$90K	Hold	130	–	–	0.09%	74
2022 Q2	$77K	Buy	+130	New	+$84.5K	0.08%	79

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Maryland Capital Advisors's REGN Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 65 shares worth $40.5K. The stake represents 0.01% of the portfolio and ranks #154 among its holdings. This is a return to the name: Maryland Capital Advisors previously reported a position in REGN as recently as Q4 2025.

Maryland Capital Advisors first reported a position in REGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $137K in Q3 2024. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Maryland Capital Advisors held 65 shares of Regeneron Pharmaceuticals worth $40.5K as of Q2 2026.
Regeneron Pharmaceuticals was a new Maryland Capital Advisors position in Q2 2026.
Regeneron Pharmaceuticals made up 0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #154 holding.
Maryland Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Maryland Capital Advisors's Regeneron Pharmaceuticals position peaked at $137K in Q3 2024.
729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.